SMTL ID : 8ruu.1

Fabs derived from bimekizumab in complex with IL-17F

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.81 Å

Oligo State

hetero-2-2-2-mer

Ligands

1 x NAG- NAG- BMA- MAN- FUL: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[beta-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose

NAG-NAG-BMA-MAN-FUL.1: 6 residues within 4Å: Chain A: E.104 Chain C: N.43, E.45, S.46, N.53, R.73 1 PLIP interactions: 1 interactions with chain C Hydrogen bonds: C:S.46

1 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)

NAG.2: 4 residues within 4Å: Chain D: E.104 Chain F: S.46, N.53, R.73 1 PLIP interactions: 1 interactions with chain F Hydrophobic interactions: F:N.53

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Adams, R. et al., Crystal Structure of Bimekizumab Fab Fragment in Complex with IL-17F Provides Molecular Basis for Dual IL-17A and IL-17F Inhibition. J Invest Dermatol. (2024)

Release Date

2024-04-24

Peptides

Immunoblobulin heavy chain: AD
Immunoblobulin light chain: BE
Interleukin-17F: CF

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
B

D
H

B
C

E
L

C
X

F
Y

Immunoblobulin heavy chain

Immunoblobulin light chain

Interleukin-17F

Related Entries With Identical Sequence